Invectys awarded “2023 Best Translational Development” by the MATWIN international Board Houston, TX, USA, May 26, 2023 – Invectys Inc., a clinical-stage…
Invectys is part of project “Melomanes”! Melomanes is a multidisciplinary project, which aims to develop a novel combination treatment for metastatic melanoma,…
INVECTYS, INC. TO PARTICIPATE IN THE 41ST JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023 Houston, Texas, January 5, 2023 – Invectys, Inc. “Invectys”,…
Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy FDA granted IND clearance for IVS-3001, Invectys’s lead…
FRANÇOIS LESCURE, GENERAL MANAGER OF INVECTYS SAS, TO PARTICIPATE IN THE ABBVIE PARTNERING DAY IN PARIS, FRANCE ON OCTOBER 4TH, 2022 Paris, France, September…
9th International Conference on HLA-G July 4th – 5th 2022 Fondation Singer-Polignac, 43 Avenue Georges Mandel, 75116 Paris Invectys will be…
Invectys, MD Anderson and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development Houston, Texas, USA – June 16, 2022 – Invectys, Inc. (Invectys),…
Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS Houston, Texas, USA – April 11, 2022 (GLOBE NEWSWIRE) –…
